340B Drug Pricing Program
The AHA today issued a Regulatory Advisory that includes a detailed summary of the Health Resources and Services Administration announcement on the new 340B Rebate Model Program
The 340B Drug Pricing Program was established by Congress to ensure that hospitals serving low-income, rural and medically underserved communities are able to stretch limited federal resources and use their savings to maintain, improve and expand access to care.
On Aug. 3, the Health Resources and Services Administration (HRSA) issued a Federal Register notice announcing a new 340B Rebate Model Program.
The AHA hosted a webinar for members on Aug. 5, during which AHA staff discussed the recently released CY 2027 Physician Fee Schedule proposed rule. The proposed rule includes updates to physician fee schedule rates and other aspects of physician payment. It also contains proposals related to the…
The Centers for Medicare & Medicaid Services (CMS) is seeking comments on its hospital outpatient prospective payment system proposed rule for calendar year 2027. Comments are due to CMS by Aug. 31.
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act), a bill aimed at providing statutory clarity for the 340B Drug Pricing Program while establishing new…
A bipartisan group of senators today introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act),
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers to use rebates rather than upfront discounts to effectuate the 340B ceiling price for certain drugs purchased by 340B covered entities.
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers to use rebates rather than upfront discounts to effectuate the 340B ceiling price for certain drugs purchased by 340B covered entities.
The AHA is deeply concerned that HHS has chosen to move forward with a 340B Rebate Model Program despite the overwhelming evidence that it will impose massive new administrative and financial burdens on hospitals that serve America's most vulnerable patients.